{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,1]],"date-time":"2026-10-01T21:22:36Z","timestamp":1790889756688,"version":"4.1.0"},"reference-count":39,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2026,2,1]],"date-time":"2026-02-01T00:00:00Z","timestamp":1769904000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,2,1]],"date-time":"2026-02-01T00:00:00Z","timestamp":1769904000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,2,1]],"date-time":"2026-02-01T00:00:00Z","timestamp":1769904000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2026,2,1]],"date-time":"2026-02-01T00:00:00Z","timestamp":1769904000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2026,2,1]],"date-time":"2026-02-01T00:00:00Z","timestamp":1769904000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2026,2,1]],"date-time":"2026-02-01T00:00:00Z","timestamp":1769904000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2026,2,1]],"date-time":"2026-02-01T00:00:00Z","timestamp":1769904000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"funder":[{"DOI":"10.13039\/100010414","name":"Health Research Board","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100010414","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001584","name":"Department of Agriculture, Food and the Marine, Ireland","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100001584","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100008303","name":"Northern Ireland Department for Employment and Learning","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100008303","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Bone"],"published-print":{"date-parts":[[2026,2]]},"DOI":"10.1016\/j.bone.2025.117710","type":"journal-article","created":{"date-parts":[[2025,11,6]],"date-time":"2025-11-06T01:50:52Z","timestamp":1762393852000},"page":"117710","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":4,"special_numbering":"C","title":["Angiotensin receptor blockers (ARBs) but not angiotensin converting enzyme inhibitors (ACE-Is) are associated with lower osteoclast activity and higher bone mineral density: Results from the TUDA study"],"prefix":"10.1016","volume":"203","author":[{"given":"Donal","family":"Fitzpatrick","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Eamon","family":"Laird","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mary","family":"Ward","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Leane","family":"Hoey","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Catherine F.","family":"Hughes","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Liadhan","family":"McAnena","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"J.J.","family":"Strain","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Conal","family":"Cunningham","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anne M.","family":"Molloy","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Helene","family":"McNulty","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rosaleen","family":"Lannon","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kevin","family":"McCarroll","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"13","key":"10.1016\/j.bone.2025.117710_bb0005","doi-asserted-by":"crossref","first-page":"125","DOI":"10.1007\/s12018-015-9189-6","article-title":"The renin\u2013angiotensin system and bone","author":"Tamargo","year":"2015","journal-title":"Clin. Rev. Bone Miner. Metab."},{"issue":"3","key":"10.1016\/j.bone.2025.117710_bb0010","doi-asserted-by":"crossref","first-page":"217","DOI":"10.1007\/s00223-012-9671-9","article-title":"The relationship among hypertension, antihypertensive medications, and osteoporosis: a narrative review","volume":"92","author":"Ili\u0107","year":"2013","journal-title":"Calcif. Tissue Int."},{"issue":"2","key":"10.1016\/j.bone.2025.117710_bb0015","doi-asserted-by":"crossref","first-page":"426","DOI":"10.3390\/biomedicines13020426","article-title":"Angiotensin II promotes osteocyte RANKL expression via AT1R activation","volume":"13","author":"Ren","year":"2025","journal-title":"Biomedicines"},{"issue":"15","key":"10.1016\/j.bone.2025.117710_bb0020","doi-asserted-by":"crossref","first-page":"11963","DOI":"10.3390\/ijms241511963","article-title":"The relationship between renin\u2013angiotensin\u2013aldosterone system (RAAS) Activity, osteoporosis and estrogen deficiency in type 2 diabetes","volume":"24","author":"Mkhize","year":"2023","journal-title":"Int. J. Mol. Sci."},{"issue":"4(4)","key":"10.1016\/j.bone.2025.117710_bb0025","doi-asserted-by":"crossref","first-page":"584","DOI":"10.1016\/j.bone.2005.09.011","article-title":"Angiotensin converting enzyme inhibitor use is associated with higher bone mineral density in elderly Chinese","volume":"38","author":"Lynn","year":"2006","journal-title":"Bone"},{"issue":"2","key":"10.1016\/j.bone.2025.117710_bb0030","doi-asserted-by":"crossref","first-page":"297","DOI":"10.1007\/s00198-005-2019-9","article-title":"The determinants of bone mineral density in Chinese men\u2014results from MrOs (Hong Kong), the first cohort study on osteoporosis in Asian men","volume":"17","author":"Lau","year":"2006","journal-title":"Osteoporos. Int."},{"issue":"10","key":"10.1016\/j.bone.2025.117710_bb0035","doi-asserted-by":"crossref","first-page":"2039","DOI":"10.1007\/s00198-019-05041-3","article-title":"The renin-angiotensin aldosterone system and osteoporosis: findings from the Women\u2019s Health Initiative","volume":"30","author":"Carbone","year":"2019","journal-title":"Osteoporos. Int."},{"issue":"8","key":"10.1016\/j.bone.2025.117710_bb0040","doi-asserted-by":"crossref","first-page":"2159","DOI":"10.1007\/s00198-011-1831-7","article-title":"Does the use of ACE inhibitors or angiotensin receptor blockers affect bone loss in older men?","volume":"23","author":"Kwok","year":"2012","journal-title":"Osteoporos. Int."},{"issue":"1","key":"10.1016\/j.bone.2025.117710_bb0045","first-page":"17","article-title":"Effect of angiotensin converting enzyme inhibitor and benzodiazepine intake on bone loss in older Japanese","volume":"57","author":"Masunari","year":"2008","journal-title":"Hiroshima J. Med. Sci."},{"issue":"1","key":"10.1016\/j.bone.2025.117710_bb0050","doi-asserted-by":"crossref","first-page":"94","DOI":"10.1007\/s11657-017-0387-3","article-title":"Long-term use of angiotensin-converting enzyme inhibitors protects against bone loss in African-American elderly men","volume":"12","author":"Rianon","year":"2017","journal-title":"Arch. Osteoporos."},{"issue":"11","key":"10.1016\/j.bone.2025.117710_bb0055","doi-asserted-by":"crossref","first-page":"947","DOI":"10.1007\/s10654-017-0285-4","article-title":"Renin-angiotensin system inhibitors and risk of fractures: a prospective cohort study and meta-analysis of published observational cohort studies","volume":"32","author":"Kunutsor","year":"2017","journal-title":"Eur. J. Epidemiol."},{"issue":"3","key":"10.1016\/j.bone.2025.117710_bb0060","doi-asserted-by":"crossref","first-page":"732","DOI":"10.1007\/s12020-016-1201-5","article-title":"ACE inhibitors and the risk of fractures: a meta-analysis of observational studies","volume":"55","author":"Cheng","year":"2017","journal-title":"Endocrine"},{"key":"10.1016\/j.bone.2025.117710_bb0065","doi-asserted-by":"crossref","DOI":"10.1155\/2022\/7581110","article-title":"Angiotensin receptor blocker is associated with a lower fracture risk: an updated systematic review and meta-analysis","volume":"2022","author":"Wu","year":"2022","journal-title":"Int. J. Clin. Pract."},{"key":"10.1016\/j.bone.2025.117710_bb0070","doi-asserted-by":"crossref","first-page":"1164387","DOI":"10.3389\/fendo.2023.1164387","article-title":"Association of antihypertensive drugs with fracture and bone mineral density: a comprehensive drug-target Mendelian randomization study","volume":"14","author":"Huang","year":"2023","journal-title":"Front. Endocrinol."},{"issue":"1","key":"10.1016\/j.bone.2025.117710_bb0075","doi-asserted-by":"crossref","first-page":"137","DOI":"10.1007\/s11657-021-01004-6","article-title":"Association between bone measures and use of angiotensin-converting enzyme inhibitors or angiotensin II receptor blockers","volume":"16","author":"Holloway-Kew","year":"2021","journal-title":"Arch. Osteoporos."},{"issue":"1","key":"10.1016\/j.bone.2025.117710_bb0080","doi-asserted-by":"crossref","first-page":"797","DOI":"10.1186\/s12891-024-07909-w","article-title":"Association of RAAS inhibitors on osteoporosis and fracture risk in the hypertensive population-a prospective population-based cohort study in Lanzhou, China","volume":"25","author":"Yin","year":"2024","journal-title":"BMC Musculoskelet. Disord."},{"issue":"5","key":"10.1016\/j.bone.2025.117710_bb0085","doi-asserted-by":"crossref","first-page":"847","DOI":"10.1093\/ageing\/afv090","article-title":"Determinants of 25-hydroxyvitamin D in older Irish adults","volume":"44","author":"McCarroll","year":"2015","journal-title":"Age Ageing"},{"issue":"9","key":"10.1016\/j.bone.2025.117710_bb0090","doi-asserted-by":"crossref","first-page":"954","DOI":"10.1007\/s12603-016-0845-4","article-title":"Dairy intakes in older irish adults and effects on vitamin micronutrient status: data from the TUDA study","volume":"21","author":"Laird","year":"2017","journal-title":"J. Nutr. Health Aging"},{"key":"10.1016\/j.bone.2025.117710_bb0095","series-title":"Dietary Reference Intakes for Calcium and Vitamin D [Internet]. National Academies Press (US)","article-title":"Institute of Medicine (US) committee to review dietary reference intakes for vitamin d and calcium","author":"Ross","year":"2011"},{"issue":"12","key":"10.1016\/j.bone.2025.117710_bb0100","doi-asserted-by":"crossref","first-page":"2443","DOI":"10.1002\/jbmr.4709","article-title":"A 2-year randomized controlled trial with low-dose B-vitamin supplementation shows benefits on bone mineral density in adults with lower B12 status","volume":"37","author":"Clements","year":"2022","journal-title":"J. Bone Miner. Res."},{"issue":"11","key":"10.1016\/j.bone.2025.117710_bb0105","doi-asserted-by":"crossref","first-page":"2255","DOI":"10.1161\/HYPERTENSIONAHA.123.21648","article-title":"Advanced progress of the relationship between antihypertensive drugs and bone metabolism","volume":"80","author":"Zhang","year":"2023","journal-title":"Hypertension"},{"key":"10.1016\/j.bone.2025.117710_bb0110","doi-asserted-by":"crossref","first-page":"475","DOI":"10.1007\/164_2019_340","article-title":"Drugs causing bone loss","volume":"262","author":"Vestergaard","year":"2020","journal-title":"Handb. Exp. Pharmacol."},{"issue":"7","key":"10.1016\/j.bone.2025.117710_bb0115","doi-asserted-by":"crossref","first-page":"1269","DOI":"10.1111\/jgs.15258","article-title":"Effect of area-level socioeconomic deprivation on risk of cognitive dysfunction in older adults","volume":"66","author":"McCann","year":"2018","journal-title":"J. Am. Geriatr. Soc."},{"issue":"4","key":"10.1016\/j.bone.2025.117710_bb0120","doi-asserted-by":"crossref","first-page":"632","DOI":"10.1002\/jbmr.3641","article-title":"Change in bone density and reduction in fracture risk: a meta-regression of published trials","volume":"34","author":"Bouxsein","year":"2019","journal-title":"J. Bone Miner. Res."},{"issue":"1","key":"10.1016\/j.bone.2025.117710_bb0125","doi-asserted-by":"crossref","first-page":"29","DOI":"10.1002\/jbmr.4433","article-title":"Validation of the surrogate threshold effect for change in bone mineral density as a surrogate endpoint for fracture outcomes: the FNIH-ASBMR SABRE project","volume":"37","author":"Eastell","year":"2022","journal-title":"J. Bone Miner. Res."},{"issue":"3","key":"10.1016\/j.bone.2025.117710_bb0130","doi-asserted-by":"crossref","first-page":"288","DOI":"10.1007\/s00223-022-00996-8","article-title":"Bone turnover marker profiling and fracture risk in older women: fracture risk from age 75 to 90","volume":"111","author":"Ivaska","year":"2022","journal-title":"Calcif. Tissue Int."},{"issue":"3","key":"10.1016\/j.bone.2025.117710_bb0135","doi-asserted-by":"crossref","first-page":"386","DOI":"10.1359\/JBMR.0301244","article-title":"Biochemical markers of bone metabolism and prediction of fracture in elderly women","volume":"19","author":"Gerdhem","year":"2004","journal-title":"J. Bone Miner. Res."},{"issue":"6","key":"10.1016\/j.bone.2025.117710_bb0140","doi-asserted-by":"crossref","first-page":"666","DOI":"10.1007\/s00774-012-0363-3","article-title":"The effect of angiotensin-converting enzyme inhibitor use on bone loss in elderly Chinese","volume":"30","author":"Feng","year":"2012","journal-title":"J. Bone Miner. Metab."},{"issue":"8","key":"10.1016\/j.bone.2025.117710_bb0145","doi-asserted-by":"crossref","first-page":"1064","DOI":"10.1111\/ggi.12406","article-title":"Effect of angiotensinII receptor blocker, olmesartan, on turnover of bone metabolism in bedridden elderly hypertensive women with disuse syndrome","volume":"15","author":"Aoki","year":"2015","journal-title":"Geriatr. Gerontol. Int."},{"issue":"3","key":"10.1016\/j.bone.2025.117710_bb0150","article-title":"Effects of telmisartan and losartan treatments on bone turnover markers in patients with newly diagnosed stage I hypertension","volume":"20","author":"Aydo\u011fan","year":"2019","journal-title":"J. Renin-Angiotensin-Aldosterone Syst. JRAAS."},{"issue":"1","key":"10.1016\/j.bone.2025.117710_bb0155","first-page":"276","article-title":"Efecto de telmisartan sobre marcadores del remodelado \u00f3seo en pacientes hipertensos (Telmisartan\u2019s effect on remodelling bone markers in hypertensive patients)","volume":"27","author":"P\u00e9rez-Castrill\u00f3n","year":"2012","journal-title":"Nutr. Hosp."},{"issue":"1","key":"10.1016\/j.bone.2025.117710_bb0160","doi-asserted-by":"crossref","first-page":"F37","DOI":"10.1152\/ajprenal.00519.2009","article-title":"Major role for ACE-independent intrarenal ANG II formation in type II diabetes","volume":"298","author":"Park","year":"2010","journal-title":"Am. J. Physiol. Renal Physiol."},{"key":"10.1016\/j.bone.2025.117710_bb0165","doi-asserted-by":"crossref","first-page":"772","DOI":"10.1007\/s00774-020-01132-y","article-title":"Role of the renin\u2013angiotensin\u2013aldosterone system in bone metabolism","volume":"38","author":"Mo","year":"2020","journal-title":"J. Bone Miner. Metab."},{"key":"10.1016\/j.bone.2025.117710_bb0170","article-title":"The effect of the angiotensin-converting enzyme inhibitor on bone health in castrated hypertensive rats is mediated via the Kinin-Kallikrein system","volume":"2022","author":"Zhang","year":"2022","journal-title":"J. Renin-Angiotensin-Aldosterone Syst. JRAAS."},{"key":"10.1016\/j.bone.2025.117710_bb0175","doi-asserted-by":"crossref","first-page":"44","DOI":"10.1016\/j.ejphar.2017.04.031","article-title":"The ACE-2\/Ang1-7\/Mas cascade enhances bone structure and metabolism following angiotensin-II type 1 receptor blockade","volume":"807","author":"Abuohashish","year":"2017","journal-title":"Eur. J. Pharmacol."},{"key":"10.1016\/j.bone.2025.117710_bb0180","doi-asserted-by":"crossref","DOI":"10.3389\/fendo.2023.1207502","article-title":"Azilsartan inhibits inflammation-triggered bone resorption and osteoclastogenesis in vivo via suppression of TNF-\u03b1 expression in macrophages","volume":"14","author":"Fan","year":"2023","journal-title":"Front. Endocrinol."},{"key":"10.1016\/j.bone.2025.117710_bb0185","doi-asserted-by":"crossref","DOI":"10.1155\/2018\/8491092","article-title":"Associations between ACE-inhibitors, angiotensin receptor blockers, and lean body mass in community dwelling older women","volume":"2018","author":"Bea","year":"2018","journal-title":"J. Aging Res."},{"issue":"4","key":"10.1016\/j.bone.2025.117710_bb0190","doi-asserted-by":"crossref","first-page":"579","DOI":"10.1007\/s00198-025-07422-3","volume":"36","author":"Bhattoa","year":"2025","journal-title":"Osteoporos. Int. J. Establ. Result Coop. Eur. Found. Osteoporos. Natl. Osteoporos. Found. USA."},{"issue":"10","key":"10.1016\/j.bone.2025.117710_bb0195","doi-asserted-by":"crossref","first-page":"1434","DOI":"10.1093\/jbmr\/zjae126","article-title":"The relationship between treatment-related changes in total hip BMD measured after 12, 18, and 24 mo and fracture risk reduction in osteoporosis clinical trials: the FNIH-ASBMR-SABRE project","volume":"39","author":"Vilaca","year":"2024","journal-title":"J. Bone Miner. Res."}],"container-title":["Bone"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S8756328225003229?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S8756328225003229?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,6,10]],"date-time":"2026-06-10T07:45:51Z","timestamp":1781077551000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S8756328225003229"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,2]]},"references-count":39,"alternative-id":["S8756328225003229"],"URL":"https:\/\/doi.org\/10.1016\/j.bone.2025.117710","relation":{},"ISSN":["8756-3282"],"issn-type":[{"value":"8756-3282","type":"print"}],"subject":[],"published":{"date-parts":[[2026,2]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Angiotensin receptor blockers (ARBs) but not angiotensin converting enzyme inhibitors (ACE-Is) are associated with lower osteoclast activity and higher bone mineral density: Results from the TUDA study","name":"articletitle","label":"Article Title"},{"value":"Bone","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.bone.2025.117710","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2025 Elsevier Inc. All rights are reserved, including those for text and data mining, AI training, and similar technologies.","name":"copyright","label":"Copyright"}],"article-number":"117710"}}